HeartBeam Secures FDA Clearance for 3D ECG, ROTH Capital Initiates Buy Rating
Introduction
HeartBeam Inc. (NASDAQ: BEAT) is a Santa Clara, California–based medical technology company founded in 2015. The firm has developed a cable-free, credit-card-sized device—AIMIGo™—that captures ECG signals in three non-coplanar directions and synthesizes them into a 12-lead ECG. This portable platform is designed for at-home use, facilitating the detection of arrhythmias and timely interventions outside of traditional medical facilities.
Corporate Structure and Experience
HeartBeam employs between 11 and 50 individuals, according to its LinkedIn profile. The company holds over 20 issued patents related to its 3D ECG technology and algorithms. Its sector classification is Healthcare Providers & Services (NAICS 923120; SIC 5045). Investor relations are managed by MZ North America (Chris Tyson, Executive Vice President), and VStock Transfer serves as the company's transfer agent.
ECG technology by Theo
Developments and News
- December 2024: The U.S. Food and Drug Administration (FDA) granted clearance for HeartBeam’s 3D ECG technology for arrhythmia assessment.
- Under FDA review: The software module that synthesizes a 12-lead ECG from the AIMIGo device.
- August 13, 2025: Filing of Form 10-Q for the quarter ended June 30, 2025, detailing operational and financial results for the first half of 2025.
- November 13, 2025: The company held its Q3 2025 earnings call, led by CEO Rob Eno and CFO Timothy Cruickshank, discussing regulatory and commercial developments.
- November 21, 2025: Filing of Form 8-K (item 8.01), reflecting material corporate developments as required by the SEC.
- ROTH Capital Partners initiated analyst coverage with a Buy rating and a $4.00 price target, referencing anticipated FDA clearance for the 12-lead ECG synthesis software.
- PatentVest ranked HeartBeam second among 243 companies analyzed for innovation in 12-lead ECG technology, following GE HealthCare.
- HeartBeam announced a strategic partnership with HeartNexus to provide on-demand cardiologist review integrated into its at-home monitoring platform.
Financial and Strategic Aspects
As of November 21, 2025, key trading metrics were:
| Metric | Value |
|---|---|
| Share price | $0.6447 |
| Year-to-date change | –61.62 % |
| Daily volume | 2,308,292 |
| Exchange | NASDAQ (BEAT) |
Strategically, HeartBeam positions its cable-free 3D ECG approach as a differentiator in remote cardiac monitoring. The company’s patent portfolio supports its technology foundation, while the ongoing FDA review of the 12-lead synthesis software may serve as a catalyst for market adoption. Partnerships such as the one with HeartNexus aim to enhance clinical support services and patient engagement.
Market Position and Industry Context
HeartBeam operates in the digital health and remote monitoring segment of the medical device market. The trend toward decentralized healthcare is increasing demand for portable, patient-centric cardiac diagnostics. In this context, HeartBeam’s FDA-cleared arrhythmia assessment technology and pending 12-lead ECG software are significant. Recognition by PatentVest and analyst coverage by ROTH Capital suggest growing industry interest in HeartBeam's technology and regulatory advancements. Competitors in the ECG and wearable-monitoring markets include established device manufacturers, diagnostics firms, and emerging telehealth platforms.
tl;dr
- On December 21, 2024, HeartBeam received FDA clearance for its cable-free 3D ECG arrhythmia assessment device; the 12-lead ECG software remains under review.
- Q3 2025 earnings call held on November 13, 2025, addressed commercial-readiness and regulatory timelines.
- ROTH Capital Partners initiated coverage with a Buy rating and $4 price target.
- PatentVest ranked HeartBeam second in 12-lead ECG innovation among 243 firms analyzed.
- Partnership with HeartNexus launched to provide on-demand cardiologist review via the at-home platform.